• Skip to content
  • Skip to navigation
  • Skip to footer
AstraZeneca logo AstraZeneca logo
AstraZeneca logo AstraZeneca logo
  • What science can do
    What science can do
    • Stories of impact
    • Publications
  • R&D
    R&D
    • Our approach
      Our approach to R&D
      • Oncology R&D strategy
      • Rare Disease R&D Strategy
      • STEM at AstraZeneca
    • Innovation in medicines
      Innovation in medicines overview
      • Cell therapies
      • Oligonucleotide therapeutics
    • Science & Technologies
      Science & Technologies overview
      • AI and data
      • Genomics
    • Patient Commitment
    • R&D Collaborations
    • Our R&D centres
    Featured website AstraZeneca Clinical Trials Clinical trial website thumbnail Featured website Open Innovation OpenInnovation logo
  • Our therapy areas
    Our therapy areas
    • Oncology
    • BioPharmaceuticals
    • Cardiovascular, Renal and Metabolism
    • Respiratory & Immunology
    • Infectious Disease
    • Rare Disease
    • Pipeline
    • All medicines
  • Our company
    Our company
    • Our history
    • Our leadership
    • Cambridge
    • Gothenburg
    • Gaithersburg
  • Careers
    Careers
    • Great place to work
    • Inclusion and diversity
    • Learning and development
    • Employee resource groups
  • Investors
    Investor Relations (Global)
    • Investor Relations (Sweden)
    • Resources
    • Governance
    • Shareholder information
    • Dividend policy
    • Key facts
    • FAQs
    • Debt Investors
    • Investor Relations contacts
    • Annual Report 2025
    Feature Results and presentations ipad image
  • Media
    Media
    • Press Releases
    • Articles
    • Image library
    • Archive
    • Media contacts
  • Sustainability
    Sustainability
    • Climate change
      Climate change overview
      • Renewables
      • Product sustainability
      • Electric vehicles and Sustainable transport
    • Nature
      Nature overview
      • Water stewardship
      • Pharmaceuticals in the environment
      • Waste and circularity
      • AZ Forest
    • Health equity
      Health equity overview
      • Science
      • Healthcare delivery
      • Community investment
    • Health systems resilience
      Health systems resilience overview
      • Partnership for Health System Sustainability and Resilience (PHSSR)
    • Ethics and governance
      Ethics and Compliance
      • Governance
      • Sustainability governance
    • Our people
      Great place to work
      • Inclusion and diversity
      • Learning and development
      • Workforce safety and health
    • Our Values
    • Partnerships and alliances
    • Resources
      Sustainability resources
      • Our sustainability impact
    Feature Our Sustainability Impact Feature Sustainable science
  • Partnering
    Partnering
    • Our business development teams
    • Our areas of partnering interest
    • Why partner with AstraZeneca?
    • Information for Suppliers
    • Supplier Sustainability Hub
    • Sustainable procurement
    • A Catalyst Network
  • AstraZeneca Websites
  • Global site

Results 21 – 30 of 151 for vaccine Covid (0.06 seconds)

AstraZeneca’s COVID-19 vaccine provides equally effective protection against hospitalisation and deaths compared with mRNA vaccines, latest expert review shows

AstraZeneca’s COVID-19 vaccine provides equally effective protection against hospitalisation and deaths compared with mRNA vaccines, latest expert ...

14 July 2022

AstraZeneca’s COVID-19 vaccine shelf-life extended in Thailand

AstraZeneca’s COVID-19 vaccine shelf-life extended in Thailand

8 April 2022

AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine

AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine

14 August 2020

Vaxzevria approved in the EU as third dose booster against COVID-19

Vaxzevria approved in the EU as third dose booster against COVID-19

23 May 2022

AstraZeneca commences new COVID-19 vaccine supply chain in Thailand

AstraZeneca commences new COVID-19 vaccine supply chain in Thailand

2 June 2021

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

30 April 2020

AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan

AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan

21 May 2021

Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19

Vaxzevria receives full Marketing Authorisation in the EU for the prevention of COVID-19

1 November 2022

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause

9 September 2020

AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX

AstraZeneca advances mass global rollout of COVID-19 vaccine through COVAX

2 March 2021

Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next

AstraZeneca Websites

This website is intended for people seeking information on AstraZeneca's worldwide business. Our country sites can be located in the AZ Network.


Veeva ID: Z4-68564
Date of next review: August 2026

Resources

  • All resources
  • Open Innovation
  • Externally sponsored scientific research
  • Medical Information for HCPs
  • US prescription assistance programmes
  • Global clinical trials information
  • Medicines
  • Report a possible side effect

Quick links

  • Media
  • Investor Relations
  • Partnering
  • Careers
  • Sustainability
  • Modern Slavery Statement
  • AZethics – Report A Concern
  • Supplier information
  • Social Media Community Guidelines

Social Media

  • Linkedn
  • Instagram
  • Facebook
  • Twitter
  • YouTube
  • Glassdoor

utility links

  • Legal notice and Terms of Use
  • Privacy notice
  • Site map
  • Contact us
  • Cookie preferences

© AstraZeneca 2026

You are now leaving AstraZeneca.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.

AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.

Cancel Continue

Important notice for users

You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.

I disagree I agree